Continuous Transdermal Delivery of L-DOPA Based on a Self-Assembling Nanomicellar System.

about

Continuous Transdermal Delivery of L-DOPA Based on a Self-Assembling Nanomicellar System.

Item

http://www.wikidata.org/entity/Q50730845

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Continuous Transdermal Delivery of L-DOPA Based on a Self-Assembling Nanomicellar System.

@en

Continuous Transdermal Delivery of L-DOPA Based on a Self-Assembling Nanomicellar System.

@nl

type

Item

label

Continuous Transdermal Delivery of L-DOPA Based on a Self-Assembling Nanomicellar System.

@en

Continuous Transdermal Delivery of L-DOPA Based on a Self-Assembling Nanomicellar System.

@nl

prefLabel

Continuous Transdermal Delivery of L-DOPA Based on a Self-Assembling Nanomicellar System.

@en

Continuous Transdermal Delivery of L-DOPA Based on a Self-Assembling Nanomicellar System.

@nl

P1476

Continuous Transdermal Delivery of L-DOPA Based on a Self-Assembling Nanomicellar System.

@en

P2093

Amnon C Sintov

http://www.w3.org/2001/XMLSchema#string

Haim V Levy

http://www.w3.org/2001/XMLSchema#string

Igor Greenberg

http://www.w3.org/2001/XMLSchema#string

P2860

Levodopa-induced dyskinesias.

Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.

N-hexanoyl chitosan stabilized magnetic nanoparticles: Implication for cellular labeling and magnetic resonance imaging.

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications.

Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?

Continuous dopaminergic stimulation--from theory to clinical practice.

Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain.

Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects.

Therapies for dopaminergic-induced dyskinesias in Parkinson disease.

Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets.

P304

1459-1468

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11095-017-2162-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28405912

http://www.w3.org/2001/XMLSchema#string

P921

self-assembly